Key Insights into AFM24 Presentation at AACR
Affimed N.V., a pioneering clinical-stage immuno-oncology company, is set to showcase its groundbreaking work on AFM24 at a notable gathering of cancer researchers and professionals. The AACR Annual Meeting, a crucial event for innovation in cancer care, will host Affimed as it presents an abstract on the promising dose optimization of AFM24, driven by cutting-edge exposure response analysis.
Details of the Upcoming Presentation
The poster titled "Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer" will highlight critical findings in this area. Engaging prominent authors in the oncology field, the session will delve into the intricacies of AFM24’s application alongside Atezolizumab, enhancing the understanding of its monotherapy usage.
When and Where to Catch the Presentation
This important presentation is scheduled for Tuesday during the conference, occurring between 9:00 AM and 12:00 PM CDT. Attendees can find the poster at Poster Section 49, Board Number 1. This opportunity not only emphasizes Affimed's commitment to innovative therapies but also reflects the collaborative effort in the cancer research community.
Understanding AFM24
AFM24 stands out as a distinct therapeutic entity, functioning as a tetravalent bispecific immune cell engager (ICE®). Its unique design enables it to activate the body’s innate immune system by binding to CD16A on immune cells, while simultaneously targeting epidermal growth factor receptors (EGFR) prevalent in various solid tumors. This dual-action approach highlights AFM24’s potential to enhance tumor cell killing through mechanisms like antibody-dependent cellular cytotoxicity and phagocytosis.
Innovative Mechanism of Action
The effectiveness of AFM24 lies in its ability to utilize EGFR as a docking site, allowing innate immune cells to recognize and eliminate cancer cells. This remarkable mechanism not only represents a leap forward in tumor-targeted therapies but also underscores Affimed's commitment to enhancing cancer treatments for patients around the world.
Affimed N.V.: A Leader in Oncology Innovation
Headquartered in Mannheim, Germany, Affimed N.V. operates at the forefront of immuno-oncology, striving to restore patients' natural abilities to combat cancer. With a dedicated team of experts in biotechnology and pharmaceuticals, the company focuses on translating the untapped capabilities of the innate immune system into effective treatment modalities. Its innate cell engagers (ICE®) are engineered on the advanced ROCK® platform, enabling the design of tailored therapies that harness the full potential of the immune system against an array of tumors.
Future Pathways in Cancer Treatment
With several ICE® molecules currently under clinical examination, Affimed is paving the way for novel treatment options. The emphasis on combination therapies and monotherapies demonstrates the versatility and potential of these immune-engaging molecules in addressing both hematologic and solid tumors. As the company continues to explore new pathways, it aims to redefine cancer care as it stands today.
Investor and Media Contact Information
For those interested in learning more about Affimed or its innovative therapies, please reach out to:
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
Email: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
Email: m.sandin@affimed.com
Frequently Asked Questions
What is AFM24?
AFM24 is a bispecific immune cell engager designed by Affimed to activate the innate immune system, specifically targeting cancer cells through EGFR binding.
Where will Affimed present its findings?
The findings on AFM24 will be presented at the AACR Annual Meeting, taking place in Chicago during the designated session.
What topics will be covered in the poster presentation?
The poster will focus on dose optimization and the combined use of AFM24 with Atezolizumab in treating advanced non-small cell lung cancer.
How does AFM24 enhance cancer treatment?
Through its unique mechanism, AFM24 engages both the innate immune system and tumor cells, enhancing tumor cell killing via immune-mediated processes.
How can one get in touch with Affimed for investor relations?
Interested parties can contact Alexander Fudukidis via the provided email or phone number for inquiries regarding investor relations.
